Chong Kun Dang introduced on Dec. 16 that it has signed a home distribution and gross sales contract with Bayer Korea for the retinal illness remedy ‘Eylea (lively ingredient: aflibercept)’.
Underneath this settlement, Chong Kun Dang shall be chargeable for the gross sales, advertising and marketing, and distribution of Eylea 2mg and 8mg formulations to clinic-level medical establishments.
Eylea is an anti-vascular endothelial progress issue (anti-VEGF) remedy used for numerous retinal illnesses together with moist age-related macular degeneration, diabetic macular edema, macular edema on account of retinal vein occlusion, and imaginative and prescient impairment attributable to choroidal neovascularization on account of pathologic myopia. It has established itself as a normal remedy for greater than 10 years and has been acknowledged for its modern therapeutic results and reliability.
Particularly, Eylea 8mg, a high-dose formulation launched final 12 months, is evaluated as having considerably improved affected person remedy comfort by sustaining the imaginative and prescient enchancment results and security of the prevailing 2mg formulation whereas extending the dosing interval to as much as 20 weeks.
Chong Kun Dang CEO Kim Younger-ju acknowledged, “Chong Kun Dang has already accrued gross sales and advertising and marketing capabilities by numerous product lineups within the ophthalmology discipline,” including, “Primarily based on our experience and gross sales capabilities within the ophthalmology illness sector, we are going to actively promote the excellence and stability of Eylea to develop the market.”
Bayer Korea CEO Lee Jin-a mentioned, “By cooperation with Chong Kun Dang, we’ve been capable of strengthen affected person entry to Eylea, which has led the anti-VEGF marketplace for greater than 10 years,” including, “Primarily based on the stable partnership between our two firms, we are going to easily present dependable remedy choices to home retinal illness sufferers and medical workers and contribute to bettering sufferers’ high quality of life.”
